JPRN-UMIN000003188已完成1 期
A phase I study of cancer vaccine with CHP-MAGE-A4 in patients with advanced cancers expressing MAGE-A4 antigen - CHP-MAGE-A4 cancer vaccine
Department of Surgery Osaka University Graduate School of Medicine0 个研究点目标入组 20 人开始时间: 2010年2月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Other serious illnesses. 2.History of immunodeficiency disease or autoimmune disease. 3.Metastatic disease to the central nervous system, unless treated and stable. 4.Other malignancy 5.Known HIV, positivity. 6.Concomitant treatment with steroids. 7.Pregnancy or lactation. 8.Lack of availability of the patient for immunological and clinical follow-up assessment.
研究者
相似试验
已完成
1 期
CHP-MAGE-A4 cancer vaccine study for refractory MAGE-A4-expressing cancerMAGE-A4-expressing refractory cancer patients (non origin-limited) or patients who refuse standard therapyJPRN-UMIN000002153The Tazuke Kofukai Medical Research Institute6
已完成
1 期
A phase I clinical study of cancer vaccine with MAGE-A4/Survivin helper peptide for patients with advanced cancers expressing MAGE-A4 or Survivin antigeMAGE-A4- or Survivin-expressing refractory cancer patients (non origin-limited) or patients who refuse standard cancer therapyJPRN-UMIN000003489Department of General Surgery, Hokkaido University Graduated School of Medicine12
已完成
不适用
A phase I clinical trial of cancer vaccine using multiple antigen epitope peptides for advanced cervical canceradvanced and recurrent cervical cancerJPRN-UMIN000003999Saitama medical university international medical center18
已完成
1 期
The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigeIntractable malignant tumors expressing MAGE-A4 antigenJPRN-UMIN000001999Department of Surgical Oncology, Hokkaido University Graduate School of Medicine18
已完成
1 期
CHP-MAGE-A4 vaccine study for patients with advanced lung cancerMAGE-A4-expressing therapy-resistant lung cancerJPRN-UMIN000001680CHP-MAGE-A4 cancer vaccine study at University of Occupational and Environmental Health, Japan6